Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Surgical Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1412225

Epithelioid Inflammatory Myofibroblastic Sarcoma Treated With Alectinib: A Case Report & Literature Review

Provisionally accepted
Xinchun Wu Xinchun Wu 1Junxi Zhu Junxi Zhu 2*Yichao Yan Yichao Yan 2*Dongfeng Niu Dongfeng Niu 3*Lin Chen Lin Chen 2*Ning Ning Ning Ning 2*Yankai Zhang Yankai Zhang 2*
  • 1 Peking University People's Hospital, Beijing, China
  • 2 International Hospital, Peking University, Beijing, Beijing Municipality, China
  • 3 Beijing Cancer Hospital, Peking University, Beijing, Beijing Municipality, China

The final, formatted version of the article will be published soon.

    Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is an extremely rare and aggressive form of inflammatory myofibroblastic tumor. Clinically, it has a high risk of relapse and peripheral organ infiltration, and it responds poorly to conventional chemotherapy. Anaplastic lymphoma kinase (ALK) inhibitors are currently the most effective targeted therapy for EIMS. This report discusses a typical case of abdominal EIMS in a 43-year-old woman. The tumors recurred rapidly within one month after surgery. Alectinib was promptly administered upon diagnosis. However, the patient developed a severe allergic reaction to the medication. After a comprehensive assessment and symptomatic treatment, her condition stabilized, leading to a favorable prognosis. This study summarizes cases of abdominal EIMS, highlights the successful use of Alectinib for treatment, and discusses the management of medication-related complications.

    Keywords: Epithelioid inflammatory myofibroblastic sarcoma, inflammatory myofibroblastic tumor, Anaplastic lymphoma kinase, Alectinib, Drug allergy

    Received: 04 Apr 2024; Accepted: 13 Aug 2024.

    Copyright: © 2024 Wu, Zhu, Yan, Niu, Chen, Ning and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Junxi Zhu, International Hospital, Peking University, Beijing, 100871, Beijing Municipality, China
    Yichao Yan, International Hospital, Peking University, Beijing, 100871, Beijing Municipality, China
    Dongfeng Niu, Beijing Cancer Hospital, Peking University, Beijing, 100142, Beijing Municipality, China
    Lin Chen, International Hospital, Peking University, Beijing, 100871, Beijing Municipality, China
    Ning Ning, International Hospital, Peking University, Beijing, 100871, Beijing Municipality, China
    Yankai Zhang, International Hospital, Peking University, Beijing, 100871, Beijing Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.